Global Network

GLOBAL 2025 VISION

Daewoong Pharmaceutical currently has the most overseas corporations and branches (8) among domestic pharmaceutical companies, and has constructed various collaboration infrastructure including research, development, manufacturing, sales, etc. with clients to supply products desired by local markets to strengthen its local competitiveness.

Furthermore, we will ceaselessly search for, hire and foster outstanding human resources from around the world and help them contribute to the development of local pharmaceutical industries to provide the foundation for them to grow into global healthcare companies.

Localization strategy

We will continuously pursue business structure and infrastructure innovation to become a company that researches, develops and distributes products desired by the market through the collaboration of local customers and employees, while contributing to the development of the local industry.

Strengthening market competitiveness

We will expand the self-management infrastructure of overseas corporation in order to procure business sustainability, while constructing a collaborative network with multiple partners such as local manufacturers, research centers and pharmaceutical companies, while the HQ directly manages core clients to continuously expand its market dominance.

Fostering global talents

We will ceaselessly find and support outstanding talents with the will and passion for global collaboration including domestic and foreign medical scientists, researchers and international students, and actively recruit human resources who wish to grow continuously with the company and help cultivate them to empower them to develop the global pharmaceutical industry.

Global Presence

Branch Operations in Asia & US: 8
R&D Centers Worldwide: 5
Partners Worldwide: 100+

USA Rockville

Daewoong America Daewoong America Inc.: Office Research Institute Address 1 Church St. STE 103, Rockville, MD 20850, USA. TEL +1-301-309-1957 FAX +1-301-309-1957; Daewoong Pharmaceutical has continued exchange with multiple local research groups to enter the US market since 2006 and it established a local corporation in Maryland in December 2009. It plans to gain a foothold in the US market with products such as its flagship product URSA, as well as generics and improved new oral drugs. In particular, as launching in the US market nears, we will engage in ongoing C&D activities and implement new pharmaceutical technologies and export new drugs/technologies to continue to lead R&D globalization.

Vietnam Ho chi Minh

Vietnam Branch Daewoong Pharmaceutical Vietnam Representative Office: Office Address Unit 3, 7th Floor, A&B Tower, 76A Le Lai Street, Ben Thanh Ward, District 1, Ho Chi Minh City TEL +84-283-910-2114~6 FAX +84-283-910-2117; Daewoong Pharmaceutical opened its representative office in Vietnam as its first overseas branch in 2004 to begin its global business. Since entering the Vietnamese market, we have focused on the gastrointestinal therapeutic area, building a strong brand presence centered around key products such as URSA (UDCA), one of Daewoong’s flagship products. In addition, we are actively pursuing technology transfer initiatives to localize production, aiming to develop Vietnam into a core manufacturing base for the ASEAN market.

India Hyderabad

India Corporation Daewoong Pharmaceutical (India) Pvt. Ltd.: Office Research Institute Address Plot No. 5A, APIIC, IE, Prashanth Nagar, Kukatpally, Hyderabad – 500072, INDIA TEL +91-40-4466-8800 FAX +91-40-4466-8811; Daewoong Pharmaceutical opened an office in Hyderabad in November 2012 to enter India’s domestic market. In order to pioneer the biopharmaceutical market with growth potential according to the assertive support of the Indian government, Nabota was approved and released, and products such as epidermal growth factors and growth hormones will also be introduced. A research center was opened in India and it has been expanding its business to services customized to customers such as research, development, production and authorization based on the core capacities that it has accumulated over many years. Furthermore, due to the growing interest and needs for healthcare with the economic growth of the Indian market, we plan to expand products and achieve Daewoong branding through business partnership networks in the medical instrument and cosmetics sector.

Indonesia Jakarta

Indonesia Branch PT Daewoong Pharmaceutical Company Indonesia: Office Address 27th UOB Plaza Unit 5, MH Thamrin No. 10, Jakarta 10230, Indonesia TEL +62-21-3048-2266 FAX +62-21-3048-2269; Since opening its local corporation in Jakarta in 2005, Daewoong Pharmaceutical has been expanding its business using various business models through strategic partnerships with major pharmaceutical companies in Indonesia. In addition to the ordinary export supply model, we are also investing in businesses to locally produce the raw ingredients and final products of biopharmaceuticals for the first time in Indonesia through joint ventures. In particular, we are paving the cornerstone in becoming the top biopharmaceutical product in Indonesia by releasing the locally produced EPO (product name: Epodion) and we have achieved a 40% market share in just one year since entering the local market. Furthermore, it is engaging in marketing activities focusing on data and evidence and it is also continuously pursuing reverse innovation through research cooperation activities such as establishing a joint research center with the University of Indonesia.

Indonesia Surabaya

Daewoong Infion PT Daewoong Infion: Research Institute a manufacturing plant Address Jl. Raya Kasri No. 153, Desa Tawangrejo Kec. Pandaan Indonesia TEL 070-8015-2388; Daewoong Infion started as a joint venture in 2012 and received the outstanding biopharmaceutical technologies of Daewoon Pharmaceutical and is being operated as the research, development and production base of biopharmaceutical products based in Indonesia. EPO (Erythropoietin) received approval as a biosimilar for the first time in Indonesia and is currently selling the product on the market and it has also conducted technology transfers of various Daewoong Pharmaceuticals bio product such as EGF (epidermal growth factor), hGH (human growth hormone), etc. We are exploring and researching new bio drugs through open collaboration with local universities and research centers and conducting clinical studies on EPO (Epodion) to make Daewoong Pharmaceutical’s the mecca of biopharmaceuticals. We were recognized for our contributions to the health of the citizens of Indonesia in 2017 and received the best biopharmaceutical company award from the Indonesia food and drug safety ministry and also won the Indonesian Minister of Health and Welfare Award in November of the same year.

Japan Osaka

Japan Branch Daewoong Japan: Office Address #907 SEMBAONISIBLDG. 3-1-27 Kyutaromachi Chuo-ku, saka-shi, Osaka-fu 541-0056, Japan TEL +81-6-6121-8213; Daewoong Pharmaceutical has been operating a contact office in Japan as part of its efforts to prepare for the establishment of a Japanese corporation and to conduct market surveys and procure bridgeheads to Japan 2014. By increasing exchange with Japanese new drug companies and generic drug companies, while continuing sales activities, we are developing local business models and constructing infrastructure in raw materials and end product exports, CMO/CDMO, aesthetic product sales, etc. Since the founding of the Japanese corporation in 2017, we have been accelerating our entry and expansion in the advanced Japanese market.

China Beijing

China Branch Beijing Daewoong Pharmaceutical R&D Center Co., Ltd.: Office Address No.301-L301-5, 3rd Floor, Building 4 No. 38 East Third Ring North Road, Chaoyang District, Beijing TEL +86-10-8478-2536 FAX +86-10-8478-2506; The Daewoong Chinese office founded in 2006 is providing support for products developed by Daewoong Pharmaceutical and its subsidiaries including medicine, medical cosmetics, health products and specialized foods, etc. to enter the Chinese market. Furthermore, using our abundant registration and sales marketing experiences, we have constructed cooperative relations for various products and companies using assorted methods to enter the Chinese market. In particular, we are looking for new natural drug candidates using the abundant natural resources of China, while actively engaging in technological exchange by forming networks with prominent Chinese research institutes and pharmaceutical companies, while procuring a variety of DDS technologies.

China Shenyang

Liaoning Daewoong Pharmaceutical Liaoning Daewoong Pharmaceutical Co.,Ltd.: Research Institute a manufacturing plant Address NO. 5, Chun-an street, Shiqiaozi ,Xihu District, Benxi, Liaoning Zip code 177000 TEL + 86-24-4556-8901 FAX + 86-24-4556-8902; Liaoning Daewoong Pharmaceutical was founded as a company specializing in internal medicines by supplying the highest quality liquid drugs in the global market by acquiring Baifeng of Liaoning, China in 2013. It completed construction of the cGMP liquid drug plant and starting with exports of Smecta to Korea in 2017, it plans to expand distribution to China, Southeast Asia and Europe. It opened a liquid drug and solid drug research institute and is working hard on developing unique new products as well.

Thailand Bangkok

Thailand Corporation Daewoong Pharmaceutical (Thailand) Co., Ltd.: Office Address 1550 Thanapoom Tower, 14Fl., New Petchburi Road, Makasan, Ratthewi, Bangkok 10400 TEL +66-2-049-4401 FAX +66-2-049-4400; Daewoong Pharma Thailand was established in 2008. Through close collaboration with global and local partners, we provide high-quality pharmaceutical products—including Eposis, Stavic, and Erdos —as well as the new drug Envlo and aesthetic product Nabota to customers across Thailand.
To become the No.1 pharmaceutical company in the Thai market, we are strengthening our global competitiveness through differentiated products, strategic marketing, and trusted partnerships.

Philippines Manila

Philippines Corporation Daewoong Pharma Philippines Inc.: Office Address Unit 1701 17th Floor One world Place, 32nd Street Bonifacio Global City, Philippines. TEL +63-2-851-4663 FAX +63-2-635-5541; Daewoong Pharma Philippines was established in 2007 and has been expanding its business through various strategies.
Our product portfolio has been significantly strengthened with the successful market entry of Daewoong’s flagship products, such as URSA (UDCA) and Bearse, as well as the new drugs Fexuclue and Envlo. In addition, Daewoong is achieving double-digit annual growth in the aesthetic medicine market (Nabota) and is striving to become the No.1 brand in the Philippine aesthetic sector.